Compare Eaton Corporation plc (ETN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Recursion Pharmaceuticals Inc — how do they compare? Eaton Corporation plc trades at $429.02 (market cap $164.88B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Eaton Corporation plc is far larger — about 77× Recursion Pharmaceuticals Inc's market cap, and Eaton Corporation plc pays a 1.04% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ETN | RXRX | |
|---|---|---|
Market Cap | $164.88B | $2.14B |
Volume | 2,535,086 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $459.96 | $6.79 |
52-Week Low | $315.82 | $2.84 |
Typical Hold Time | 31 Days | 22 Days |
Enterprise Value | $185.51B | $1.66B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $431.33, down 3.09% today but maintains strong analyst support with 28 buy ratings and a $502.38 consensus price target. The company demonstrates consistent earnings beats in recent quarters and benefits from strategic acquisitions in data center and aerospace markets. Technical indicators show a bullish moving average trend with neutral oscillators, while fundamentals reveal solid profitability with 12.75% net income margin and 19.71% ROE.
ETN presents a compelling investment case driven by AI data center demand and grid modernization trends, though elevated valuation multiples (P/E 43.92) warrant monitoring. Key risks include execution of recent acquisitions and competitive pressures in the electrical equipment sector. The stock offers 16% upside to consensus targets with strong institutional conviction supporting long-term growth prospects.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
